Search Results
Sep 09, 2026, 10:10 ET Cellipont Bioservices and Xiogenix Publish New White Paper on Automated Fill-Finish for Scalable Cell Therapy Manufacturing
Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and
More news about: Cellipont Bioservices
Sep 09, 2026, 08:44 ET EpilepsyGTx et Viralgen collaborent pour faire progresser le programme de thérapie génique à base d'AAV contre l'épilepsie, en vue d'un premier essai clinique chez l'humain
La collaboration avec un CDMO spécialisé dans les AAV permettra d'assurer une production à grande échelle de l'EPY201 pour le traitement de l'épilepsie focale réfractaire, qui touche 10 millions de personnes.LONDRES et SAN SEBASTIÁN, Espagne,
More news about: Viralgen
Sep 09, 2026, 07:00 ET Matica Biotechnology and Bondwell Technologies Collaborate to Advance Texas Biotech Innovation
Sept. 9, 2026 /PRNewswire/ -- Matica Biotechnology ("Matica Bio"), a Texas-based contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, today announced a collaboration with Bondwell Technologies, an innovative Texas biotechnology company developing
More news about: Matica Biotechnology, Inc.
Sep 09, 2026, 05:56 ET EpilepsyGTx y Viralgen impulsan un programa de terapia génica con vectores AAV para la epilepsia
programa de terapia génica con vectores AAV para la epilepsia antes del ensayo inicial en humanosLa colaboración con una CDMO especializada en AAV respaldará la producción escalable de EPY201 para la epilepsia focal refractaria, que afecta a 10 millones de personas.
More news about: Viralgen
Sep 09, 2026, 04:40 ET EpilepsyGTx und Viralgen arbeiten gemeinsam daran, das AAV-Gentherapieprogramm zur Behandlung von Epilepsie im Vorfeld der ersten klinischen Studie am Menschen voranzutreiben
Die Zusammenarbeit mit einem auf AAV spezialisierten CDMO wird die skalierbare Produktion von EPY201 zur Behandlung der fokalen refraktären Epilepsie unterstützen, von der 10 Millionen Menschen betroffen sind.LONDON und SAN SEBASTIÁN, Spanien,
More news about: Viralgen
Sep 09, 2026, 04:00 ET EpilepsyGTx and Viralgen collaborate to advance AAV gene therapy programme for epilepsy ahead of first-in-human trial
Collaboration with AAV-specialist CDMO will support scalable production of EPY201 for focal refractory epilepsy affecting 10 million peopleLONDON and SAN SEBASTIÁN, Spain, Sept. 9, 2026 /PRNewswire/
More news about: Viralgen
Sep 09, 2026, 04:00 ET EpilepsyGTx and Viralgen collaborate to advance AAV gene therapy programme for epilepsy ahead of first-in-human trial
Collaboration with AAV-specialist CDMO will support scalable production of EPY201 for focal refractory epilepsy affecting 10 million peopleLONDON and SAN SEBASTIÁN, Spain, Sept. 9, 2026 /PRNewswire/
More news about: Viralgen
Sep 09, 2026, 02:00 ET Just - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies
Phase 1 clinical trial evaluating JST-018, a cocktail of investigational monoclonal antibodies targeting orthopoxviruses, developed by its biologics CDMO subsidiary Just – Evotec Biologics under the U.S. Department of War's Accelerated Antibodies Program. Under the Accelerated Antibodies Program,
More news about: Evotec SE
Sep 08, 2026, 10:19 ET Pharmaceutical CDMO Market to Reach US$ 270.3 Bn by 2031, Growing at 7.2% CAGR, New Report by Wissen Research
https://www.wissenresearch.com/contact/ Key Constraints in the Pharmaceutical CDMO Industry Operating a pharmaceutical CDMO business requires continuous investment in quality systems, facility upgrades, and regulatory expertise to meet strict requirements
More news about: Wissen Research LLC
Sep 08, 2026, 09:18 ET Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business
toward sustainable CDMO profitability and strengthen the Group's financial resilience. "This decision should be viewed in the context of the company we are building," Mr. Reichman added. "Our priorities are to advance our focused NanoAb portfolio, deliver for our CDMO customers and
More news about: Scinai Immunotherapeutics Ltd.
Sep 08, 2026, 09:00 ET Rose BioSolutions Appoints David Enloe as Chief Executive Officer
Solutions, a gene therapy CDMO focused on viral vector manufacturing, and continued to lead the business following its acquisition by Lonza, where it became the company's Cell and Gene Therapy Business Unit.Mr. Enloe has extensive experience transforming and scaling CDMO businesses. As President
More news about: Rose BioSolutions
Sep 07, 2026, 06:22 ET AtomVie Global Radiopharma feiert die große Eröffnung seiner neuen, hochmodernen Produktionsstätte für Radiopharmaka in Hamilton, Ontario
September 2026 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), eine weltweit führende Contract Development and Manufacturing Organization (CDMO) in der Radiopharmazie, feierte heute die feierliche Eröffnung seiner neuen, eigens für diesen Zweck errichteten und hochmodernen Produktionsstätte
More news about: AtomVie Global Radiopharma Inc.
Sep 07, 2026, 06:15 ET AtomVie Global Radiopharma célèbre l'inauguration officielle de sa nouvelle usine de fabrication de produits radiopharmaceutiques à la pointe de la technologie à Hamilton, en Ontario
7 septembre 2026 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), une organisation de développement et de fabrication sous contrat (CDMO) de premier plan à l'échelle mondiale dans le secteur des radiopharmaceutiques, a célébré aujourd'hui l'inauguration officielle de sa nouvelle usine
More news about: AtomVie Global Radiopharma Inc.
Sep 06, 2026, 02:26 ET Resonant Clinical Solutions renforce ses capacités de thérapies de pointe et de stockage cryogénique grâce à l'acquisition de Creapharm Bioservices
pharmaceutiques et biotechnologiques, des organismes de recherche sous contrat (CRO), des organismes de développement et de fabrication sous contrat (CDMO), ainsi que des laboratoires de diagnostic et de référence.La mission de Resonant est de fournir à ses partenaires des solutions complètes et
More news about: Resonant Clinical Solutions
Sep 04, 2026, 19:14 ET AtomVie celebra la inauguración de sus nuevas instalaciones de fabricación de última generación en Hamilton
de 2026 /PRNewswire/ - AtomVie Global Radiopharma (AtomVie), una organización líder a nivel mundial de desarrollo y fabricación por contrato (CDMO) en la industria radiofarmacéutica, celebró hoy la gran inauguración de sus nuevas instalaciones de fabricación de última generación, diseñadas específicamente
More news about: AtomVie Global Radiopharma Inc.
Sep 04, 2026, 14:48 ET Resonant Clinical Solutions adquiere Creapharm Bioservices
compañías farmacéuticas y biotecnológicas, organizaciones de investigación por contrato (CRO), organizaciones de desarrollo y fabricación por contrato (CDMO) y laboratorios de diagnóstico y referencia.La misión de Resonant es empoderar a sus socios con soluciones integrales y globales para la cadena
More news about: Resonant Clinical Solutions
Sep 04, 2026, 09:46 ET AtomVie Global Radiopharma Celebrates the Grand Opening of its New State-of-the-Art Radiopharmaceutical Manufacturing Facility in Hamilton, Ontario
Sept. 4, 2026 /PRNewswire/ - AtomVie Global Radiopharma (AtomVie), a leading global Contract Development and Manufacturing Organization (CDMO) in the radiopharmaceutical industry, today celebrated the Grand Opening of its new purpose-built, state-of-the-art manufacturing facility at 10 Aeropark
More news about: AtomVie Global Radiopharma Inc.
Sep 04, 2026, 09:32 ET AtomVie Global Radiopharma Celebrates the Grand Opening of its New State-of-the-Art Radiopharmaceutical Manufacturing Facility in Hamilton, Ontario
Sept. 4, 2026 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), a leading global Contract Development and Manufacturing Organization (CDMO) in the radiopharmaceutical industry, today celebrated the Grand Opening of its new purpose-built, state-of-the-art manufacturing facility at 10 Aeropark
More news about: AtomVie Global Radiopharma Inc.
Sep 03, 2026, 10:28 ET Cellipont Bioservices' Texas Facility Has Supported Six Client Projects Expected to Reach IND Submission in 2026
patient-focused culture."About Cellipont Cellipont Bioservices is a premier Contract Development and Manufacturing Organization (CDMO) specializing in the advancement of cell therapies. With a team of industry-leading experts, Cellipont is at the forefront of cell therapy development
More news about: Cellipont Bioservices
Sep 03, 2026, 08:30 ET Reduce ADC Conjugation Risk with Consistent Antibody Quality, Upcoming Webinar Hosted by Xtalks
optimization improved consistency in antibody quality attributes and overall manufacturing performance.The webinar will also highlight how experienced CDMO support can help development teams establish reliable antibody production processes, address quality variability and progress toward downstream conjugation
More news about: Xtalks
Sep 03, 2026, 08:01 ET FIRST IN THE BALTICS: NORTHWAY BIOTECH OPENS €61 MILLION CELL THERAPY AND PERSONALIZED MEDICINE CDMO IN VILNIUS
expansion of Northway Biotech's CDMO capabilities in advanced therapies. The Northway Group has invested €61 million in the new 3,500 sq. m facility within the broader BIO CITY III development. The center significantly expands Northway Biotech's established CDMO platform across mammalian and microbial
More news about: Northway Biotech
Sep 02, 2026, 23:26 ET 亞洲生技大會台康生物藥開發平臺吸睛，劉理成談 CDMO 該往何方
的價值。」此外，他也認為，臺灣另一項值得把握的優勢，是近年快速崛起的 CDMO 領域。隨著國際藥廠愈來愈傾向將製造外包給專業合作夥伴，讓自身更專注於藥物研發，具備高品質製造能力的 CDMO 將迎來更多全球合作機會。為了提升臺灣在全球供應鏈中的能見度，臺灣 CDMO 聯盟 （Taiwan CDMO Alliance）也持續前往美國等海外市場舉辦路演，向國際藥廠推廣臺灣生技製造實力。「我們希望讓世界知道，臺灣不只有半導體，也擁有具國際競爭力的生技製造能力。」叩問下一座山在哪，台康的回答全球藥廠近年愈來愈重視供應鏈韌性，臺灣生物製藥、CDMO 與生物相似藥產業也逐
More news about: 基因線上
Sep 01, 2026, 08:00 ET Andelyn Biosciences to Scale Manufacturing for Genprex's Diabetes Gene Therapy Program
work to move this program toward the clinic."About Andelyn BiosciencesAndelyn Biosciences is a full-service cell and gene therapy CDMO focused on developing, characterizing, and producing viral vectors for gene therapy. With more than 20 years of experience, Andelyn's deep scientific
More news about: Andelyn Biosciences
Aug 31, 2026, 10:15 ET Oligonucleotide CDMO Market worth $11.14 billion by 2031 - Exclusive Report by MarketsandMarkets™
(2026–2031): 23.5%Oligonucleotide CDMO Market Trends & Insights:North America accounted for 43.2% of the oligonucleotide CDMO market in 2025.By service type, contract manufacturing accounted for the largest share (42.1%) of the oligonucleotide CDMO market in 2025.By
More news about: MarketsandMarkets
Aug 31, 2026, 01:00 ET Samsung Biologics publishes prospectus for PolyPeptide public tender offer
Aug. 31, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), through its direct Swiss subsidiary Samsung Peptide AG ("Samsung Peptide"), today published the tender offer prospectus ("Offer Prospectus") for all
More news about: Samsung Biologics